CD4 and neoplasm: Application of this protocol to human hepatocarcinoma for the isolation of specific tumor peptides from both MHC-I and MHC-II pathways allowed the creation of the first multi-epitope, multi-target, and multi-allele vaccine targeting activation of CD4+ and CD8+ T cells.